<DOC>
	<DOCNO>NCT01897389</DOCNO>
	<brief_summary>The purpose study evaluate relative bioavailability 4 new formulation abiraterone acetate compare current commercial formulation .</brief_summary>
	<brief_title>A Study Assess Relative Bioavailability 4 New Abiraterone Acetate Tablet Formulations With Respect Current Commercial Abiraterone Acetate Tablet Under Fasted Conditions Healthy Male Participants</brief_title>
	<detailed_description>This randomize ( individual assign chance study treatment ) , open-label ( individual know identity study treatment ) , 4-period , 5-treatment crossover study order evaluate relative bioavailability 4 new formulation abiraterone acetate compare current commercial formulation . Approximately 32 healthy adult male participate . The total study length 68 day . This study consist screen phase follow open-label treatment phase consist 4 single-dose treatment period separate washout period least 7 day dose . Individuals randomly assign 1 8 treatment sequence . A single dose 1000 mg abiraterone acetate give treatment period fast condition . Participants confine study center Day -1 treatment period completion 96-hour blood sample collection Day 5 treatment period . A follow-up visit occur 5 7 day last study procedure . Serial pharmacokinetic ( study body drug ) sample collect open-label treatment phase detail protocol . Safety monitor throughout study .</detailed_description>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>Agrees protocoldefined use effective contraception 1 week receive last dose study drug agree donate sperm study 1 week receive last dose study drug Body mass index 18.5 30.0 kg/m2 ( inclusive ) body weight less 50 kg Blood pressure ( lie 5 minute ) 90 140 mmHg systolic high 90 mmHg diastolic A 12lead electrocardiogram consistent normal cardiac conduction function Nonsmoker use nicotinecontaining substance within previous 2 month Laboratory value within protocoldefined parameter History current clinically significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder , lipid abnormality , significant pulmonary disease , include bronchospastic respiratory disease , diabetes mellitus , renal hepatic insufficiency , thyroid disease , neurologic psychiatric disease , infection , illness investigator considers exclude patient could interfere interpretation study result Clinically significant abnormal value hematology , clinical chemistry , urinalysis , clinically significant abnormal physical examination , vital sign , 12lead electrocardiogram screening admission study center deem appropriate investigator Screening serum testosterone level &lt; 200 ng/dL Presence sexual dysfunction medical condition would affect sexual function Use prescription nonprescription medication ( include vitamin herbal supplement ) , except acetaminophen , within 14 day first dose study drug schedule study completion History , reason believe participant history drug alcohol abuse within past 5 year Positive test drug abuse ( cannabinoids , alcohol , opiates , cocaine , amphetamine , benzodiazepine , hallucinogen , barbiturate ) screen Day 1 treatment period Known allergy study drug excipients formulation History stomach intestinal surgery resection would potentially alter absorption excretion orally administer drug ( appendectomy hernia repair allow ) Donated blood blood product substantial loss blood within 3 month first administration study drug intention donate blood blood product study Received experimental drug use experimental medical device within 1 month within period le 10 time drug 's halflife , whichever longer , first dose study drug schedule Unable swallow solid , oral dosage form whole aid water Positive test human immunodeficiency virus 1 2 antibody , hepatitis B surface antigen , hepatitis B core antibody , hepatitis C antibody Preplanned surgery procedure would interfere conduct study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Healthy volunteer</keyword>
	<keyword>Bioavailability</keyword>
	<keyword>Abiraterone acetate</keyword>
	<keyword>ZYTIGA</keyword>
</DOC>